- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Indegene Limited — Board Meeting, 29-01-2026: Outcome of Board Meeting
29-01-2026 | 06:35 pm
29-01-2026 | 06:35 pm
Indegene's board approved Q3FY26 consolidated results: Revenue ₹942.1 Cr, Profit ₹102.9 Cr. Key strategic moves include the acquisition of BioPharm for ₹914.6 Cr and Warn & Co for ₹46.4 Cr, boosting its market offerings.
No comments yet. Be the first to comment!